From: Impact of intralesional botulinum toxin type A therapy on the keloid-related quality of life
Group A | Group B | Z-value | p-value | ||
---|---|---|---|---|---|
Q1 | Item 1 | 1.3 ± 0.53 | 5.86 ± 1.563 | 10.476 | < 0.0001* |
Item 2 | 1.24 ± 0.48 | 6.42 ± 1.43 | 10.592 | < 0.0001* | |
Item 3 | 1.22 ± 0.84 | 5.88 ± 1.21 | 10.603 | < 0.0001* | |
Item 4 | 1.18 ± 0.44 | 5.16 ± 1.16 | 10.737 | < 0.0001* | |
Q2 | Item 1 | 1.4 ± 0.74 | 4.46 ± 0.709 | 10.327 | < 0.0001* |
Item 2 | 1.3 ± 0.63 | 4.4 ± 0.593 | 10.561 | < 0.0001* | |
Item 3 | 1.29 ± 0.61 | 4.42 ± 0.596 | 10.570 | < 0.0001* | |
Item 4 | 1.22 ± 0.56 | 4.23 ± 0.732 | 10.623 | < 0.0001* | |
Q3 | 1.83 ± 0.79 | 5.18 ± 0.947 | 9.977 | < 0.0001* | |
Q4 | 2.71 ± 0.83 | 5.72 ± 0.559 | 10.16 | < 0.0001* | |
Q5 | 2.05 ± 0.89 | 3.58 ± 1.499 | 6.11 | < 0.0001* | |
Q6 | 2.19 ± 0.8 | 3.3 ± 1.133 | 5.802 | < 0.0001* | |
Q7 | 2.07 ± 0.82 | 4.21 ± 1.25 | 8.249 | < 0.0001* | |
Q8 | 1.52 ± 0.78 | 2.75 ± 1.93 | 4.353 | < 0.0001* | |
Q9 | 2.95 ± 0.71 | 5.79 ± 0.411 | 10.385 | < 0.0001* | |
Q10 | 1.67 ± 0.6 | 3.93 ± 0.258 | 10.514 | < 0.0001* | |
Q11 | 1.83 ± 0.67 | 3.95 ± 0.225 | 10.393 | < 0.0001* | |
Q12 | 1.31 ± 0.58 | 3.11 ± 0.724 | 9.591 | < 0.0001* | |
Q13 | 1.08 ± 0.54 | 3.39 ± 0.75 | 10.195 | < 0.0001* | |
Q14 | 1.73 ± 0.54 | 3.96 ± 0.186 | 10.685 | < 0.0001* | |
Q15 | 1.76 ± 0.53 | 3.95 ± 0.225 | 10.687 | < 0.0001* | |
Subscale 1 | 10.17 ± 2.38 | 40.82 ± 2.752 | 10.126 | < 0.0001* | |
Subscale 2 | 7.49 ± 1.37 | 16.68 ± 1.391 | 10.104 | < 0.0001* | |
Subscale 3 | 10.2 ± 1.62 | 20.33 ± 2.747 | 10.071 | < 0.0001* | |
Subscale 4 | 7 ± 1.45 | 15.79 ± 0.453 | 10.278 | < 0.0001* | |
Total score | 34.87 ± 3.73 | 93.63 ± 3.862 | 10.045 | < 0.0001* |